Post-marketing clinical study of EPZICOM tablet (lamivudine / abacavir sulfate) - pharmacokinetic study in HIV-infected patients.

Trial Profile

Post-marketing clinical study of EPZICOM tablet (lamivudine / abacavir sulfate) - pharmacokinetic study in HIV-infected patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Lamivudine/abacavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from May 2006 to July 2006 as reported by Clinicaltrials.gov.
    • 21 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top